GlassScriptPhysician profile
Mina K Oza
NPI 1003856063
$9,774.77
in general payments reported to CMS, 2019-2025
27 companies · $1,844 in 2025
The $1,844 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $202 · 2021: $1,139 · 2022: $1,556 · 2023: $2,533 · 2024: $2,500 · 2025: $1,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,843 · Education: $34.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,843.37 |
| Education | $34.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,262.10 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $666.77 | 2021-2025 | Caplyta |
| Lundbeck LLC | $646.10 | 2021-2025 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $586.18 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Mycite |
| Vanda Pharmaceuticals INC. | $542.16 | 2024-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $517.87 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $438.60 | 2021-2025 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $421.77 | 2022-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $396.15 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $361.34 | 2020-2021 | |
| Axsome Therapeutics, INC. | $318.54 | 2022-2023 | Auvelity |
| Almatica Pharma LLC | $281.71 | 2022-2025 | Loreev Xr, Gralise |
| E.R. Squibb & Sons, L.L.C. | $192.00 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $167.00 | 2022-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $165.93 | 2023-2025 | Invega Sustenna, Spravato |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $140.71 | 2022-2025 | Aplenzin |
| Tris Pharma INC | $137.16 | 2022-2025 | Dyanavel Xr |
| Corium, LLC | $129.74 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $92.99 | 2022-2024 | Qelbree |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $75.28 | 2025 | Rejoyn, Abilify Asimtufii |
| Noven Therapeutics, LLC | $66.09 | 2020-2024 | Xelstrym, Secuado |
| Indivior INC. | $52.44 | 2022-2024 | Perseris |
| Allergan, INC. | $47.05 | 2020 | |
| Luye Pharma (USA) LTD. | $21.48 | 2025 | Erzofri Extended-Release |
| Vertical Pharmaceuticals, LLC | $18.19 | 2024 | Relexxii |
| Collegium Pharmaceutical, INC. | $15.11 | 2025 | Jornay Pm |
| Alfasigma USA, INC. | $14.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mina Oza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.